

SOMANETICS CORP
Form 8-K
February 10, 2009

OMB APPROVAL
OMB Number:
3235-0060
Expires: April 30,
2009
Estimated average
burden
hours per response 5.0

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) February 6, 2009

SOMANETICS CORPORATION

(Exact name of registrant as specified in its charter)

Michigan

0-19095

38-2394784

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

1653 East Maple Road, Troy, Michigan

48083-4208

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code (248) 689-3050

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act.
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Item 1.01. Entry into a Material Definitive Agreement

We entered into a Contract Development and Exclusive Licensing Agreement with NeuroPhysics Corporation as of September 18, 2006, which we terminated as of February 6, 2009, except for various provisions regarding our ownership of the technology related to the potential new products, as described in Item 1.02 below, which Item 1.02 is incorporated into this Item 1.01 by reference. As of February 6, 2009, we entered into a similar Contract Development Agreement with Shirley Research Corporation and Hugh F. Stoddart and Hugh A. Stoddart. The new agreement provides us with feasibility research, contract development and consulting services and certain ownership rights to intellectual property and technical knowledge associated with several novel near-infrared spectroscopy, or NIRS, and imaging technologies and products previously under development at NeuroPhysics, and have agreed to pay monthly development and consulting fees of \$15,000 a month during the term of the agreement and a royalty on future sales of the new products.

Shirley Research Corporation is in the early stage of feasibility research and development of several NIRS-based technologies and products, including a novel approach to depth resolved NIRS measurements. In addition to this NIRS-based, depth-resolved technology, products that may be developed under the agreement include (1) a fetal cerebral oximetry system, (2) a monitor for measuring oxygen saturation in deep tissues for assessing hemorrhagic shock, (3) devices to assess tumors or swelling containing blood, including in the brain of head trauma victims and neonates with intra-ventricular hemorrhage, (4) a continuous and non-invasive blood gas monitor, and (5) a new imaging concept intended to improve resolution and expand the applicability of endoscopes. We may terminate any or all of the projects under this agreement at any time. We might not be able to develop these technologies or products into commercially viable products, and competitors might develop and market similar products before we do.

Item 1.02. Termination of a Material Definitive Agreement

We entered into a Contract Development and Exclusive Licensing Agreement with NeuroPhysics Corporation as of September 18, 2006. The agreement provided us with feasibility research, contract development and consulting services and certain ownership and licensing rights, subject to the rights of the United States Federal government, to intellectual property and technical knowledge associated with several novel near-infrared spectroscopy, or NIRS, and imaging technologies and products under development at NeuroPhysics. We paid an initial license fee of \$1,000,000. We terminated this agreement as of February 6, 2009, except for various provisions regarding our ownership of the technology related to the potential new products. This termination was in connection with our entry into a similar agreement with Shirley Research Corporation and Hugh F. Stoddart and Hugh A. Stoddart as of February 6, 2009, described in Item 1.01 above, which Item 1.01 is incorporated into this Item 1.02 by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Contract Development Agreement, dated as of February 6, 2009, among Somanetics Corporation, Shirley Research Corporation, Hugh F. Stoddart, and Hugh A. Stoddart.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 10, 2009

SOMANETICS CORPORATION
(Registrant)

By: /s/ Mary Ann Victor

Mary Ann Victor

Its: Vice President and Chief Administrative
Officer and Secretary

3

EXHIBIT INDEX

Exhibit	Description
99.1	Contract Development Agreement, dated as of February 6, 2009, among Somanetics Corporation, Shirley Research Corporation, Hugh F. Stoddart, and Hugh A. Stoddart.

4